Project Details
Description
A Phase 2b, Randomized, Double-blind, Single-dose, Active-controlled, Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults who are Hospitalized with Influenza Caused by Type A Strains (protocol D6000C00003)
| Status | Finished |
|---|---|
| Effective start/end date | 7/1/16 → 12/31/17 |
Funding
- MEDIMMUNE, LLC
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.